Arena Pharma (ARNA) Announces Cost-Reduction Program; Will Trim U.S. Headcount by 35%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- S&P 500 ends marginally lower as investors focus on US-Iran war
Arena Pharmaceuticals Announces New Strategic Focus and Cost Reduction Plan
October 27, 2015 4:00 PM EDTSAN DIEGO, Oct. 27, 2015 /PRNewswire/ --Â Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced plans to improve efficiencies and reduce costs as it focuses on the advancement of its research and development priorities.
Arena intends to focus on its key strengths by concentrating near-term activities and resources primarily on:
advancing its APD334 program, including the ongoing Phase 2 clinical trial for ulcerative colitis, and potentially exploring additional indications beyond inflammatory bowel disease through small pilot studies; advancing its ralinepag (formerly known as APD811) program, including its ongoing Phase 2 clinical trial... More